• Pre Clinical And Clinical Research

Dr. Philip Beer joins CCG.ai

Dr. Philip Beer joins Cambridge Cancer Genomics as Head of Translational Medicine

Medherant positions itself for the next stage of its development with the appointment of a new CEO

Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.

Guest blog | Sean Morgan-Jones | UK Biotech PLC is Totally Smashing It...

‘The UK is leading a two speed Europe’ (McKinsey & Company, Biotech in Europe: Scaling Innovation May 20, 2019). One of the key findings and contrary to the received wisdom, is that the UK is totally smashing it on all measures as a Biotech hot spot according to research presented at BioEquity Europe in Barcelona by McKinsey & Company looking at where's hot and where's not. Of the 1,000 European Biotechs established since 2012 the UK is leading by a country mile and represents 35% of all new Biotechs and according to the report and is leading a two speed Europe (with Germany, France and Spain in relative decline). 

Video of the week | How Engineers Move Medicine Around The World

Medicines have complex storage and transportation needs, and getting medicines to remote locations requires lots of planning, clever engineering and infrastructure. Check out this video from SciShow on YouTube to find out more about how medicines are transported around the world. 

CEO Update | Tuesday 11 June 2019

Many congratulations to BIA Chair, Dr Jane Osbourn who has been awarded an OBE in the Queen’s birthday honours announced at the weekend. Jane is a true pioneer in our sector, who not only has pioneered world-class research and contributed to blockbuster discoveries but is a passionate advocate for the UK life sciences sector. For me, Jane’s greatest qualities are her abilities to communicate and lead, she has and always will be a trailblazer in our sector and I’m delighted that she has received this award. In Westminster the Conservative leadership contest to replace Theresa May is underway and we have produced a life sciences focused guide to the runners and riders which is available here.

Video of the week | What makes measles so contagious

Just this week, Public Health England said that every one person who misses a vaccination is "one too many". There have been 795 cases of mumps in the first three months of 2019, compared with 1031 cases in the whole of 2018. Measles is not far behind in terms of making a comeback, but how does the disease get such a grip, and why does it spread so fast? Check out this video from Stat news to find out more about how measles gets a grip - and remember the most effective way to prevent it is by getting vaccinated. 

UKI2S and Innovate UK launch new £10m initiative to accelerate growth of early stage science and engineering companies

The £27m UK Innovation & Science Seed Fund (UKI2S) and Innovate UK (IUK) have launched a joint initiative, the UKI2S Innovate Accelerator. With £10m of IUK funding to be used alongside direct equity investment by UKI2S, the new scheme is designed to boost some of the UK’s most exciting young companies.

CEO Update | Monday 20 May 2019

UK life science certainly feels more Champions League Final (Spurs v Liverpool) than Eurovision (UK last place) this week. First, LifeArc has announced that it has sold most of its royalty interest in the blockbuster drug Keytruda for $1.3bn (£1.02bn) and plans to invest the windfall in developing new treatments. The sale was made to the Canada Pension Plan Investment Board, one of the world’s largest retirement funds. We were thrilled that recently-appointed LifeArc CEO, Melanie Lee, was the recipient of our lifetime achievement award at the BIA Gala Dinner in January – it’s fantastic to see her leading the way on LifeArc’s monetization process. This is great news for the UK life sciences ecosystem, research and patients. You can read more about this in the Financial Times.

Lonza chooses Synpromics’ novel inducible promoter platform to manufacture biopharmaceuticals

Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.

New report unveils a thriving service and supply sector for UK medicines discovery

New report unveils a thriving service and supply sector for UK medicines discovery Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness Today [13 May 2019], Medicines Discovery Catapult and the BioIndustry Association unveil their 2019 State of the Discovery Nation report, providing new insights into the UK’s growing medicines discovery industry.